Objective: This study evaluates the effectiveness of L-arginine and leucine supplementation in preventing intrauterine growth restriction (IUGR) and improving neonatal outcomes by examining their impact on gestational age and amniotic fluid index (AFI).Material and Methods: A hospital-based observational study was conducted at Nulife Hospital, Delhiover 03 months, involving 50 pregnant women diagnosed with IUGR. Baseline assessments of gestational age and AFI were performed using ultrasound. Participants received daily L-arginine and leucine supplements. Follow-up visits occurred every four weeks. Data were analyzed using paired t-tests in MX Excel 2010. Participants provided written informed consent.Results: The study found significant improvements in both gestational age and AFI among participants. The mean gestational age increased from 21.16 weeks to 28.60 weeks, and the mean AFI improved from 9.88 cm to 11.08 cm, with an average AFI change of 1.39 cm. Statistical analysis confirmed these changes were significant, with a t-value of -13.033 (p < 0.001) for gestational age and -4.509 (p < 0.001) for AFI. The intervention showed consistent results across different delivery methods and CTG findings, suggesting broad effectiveness.Conclusion: L-arginine and leucine supplementation significantly improved gestational age and AFI in pregnancies affected by IUGR, highlighting their potential to support fetal development and optimize placental function. Further research with larger cohorts is needed to confirm these findings and establish the efficacy of these supplements in enhancing neonatal health and pregnancy outcomes.